HC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $45 Price Target
Benzinga Newsdesk 6 months ago
NewsPrice TargetReiterationAnalyst Ratings
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $45 price target.
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $45 price target.